Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 815

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 815
---
 and 2023, respectively. Note 9-Accountspayable and accrued expenses Accounts payable and accrued expenses consist of the following as of December 31, 2024, and 2023:

|                        |     |            | December 31, 
         2024 |     |            | December 31, 
         2023 |
|:-----------------------|:----|-----------:|-------------:|:----|-----------:|-------------:|
| Trade accounts payable |     |          $ |    3,152,816 |     |          $ |    1,866,762 |
| Accrued compensation   |     |            |    1,161,650 |     |            |    1,415,397 |
| Other accrued expenses |     |            |      855,700 |     |            |      156,400 |
|                        |     | $5,170,166 |              |     | $3,438,559 |              |

Note 10-Convertiblepromissory notes On various dates beginning on December 11, 2023 through September 18, 2024, the Company completed a private placement in which the Company issued Convertible Promissory Notes (the “Notes”) with various entities at various amounts for an aggregate of $31,253,000. The Notes bear interest at a rate of twenty percent (20%) per annum and were scheduled to mature on the second anniversary of the issuance date. In addition, the investors in the private placement also received common stock purchase warrants (the “2024 Warrants”) in the event they subscribe to purchase Notes in the aggregate principal amount of more than $4.0 million or more, with such number of 2024 Warrants being equal to 50% of the aggregate principal amount of the Note purchased divided by $3.80. The 2024 Warrants related to these Notes have an exercise price of $5.70 per share and expire three years from the date of issuance. On October 18, 2024, under automatic conversion features upon the occurrence of a reverse public merger transaction, the convertible notes payable converted to common stock and the derivative liability was reclassified to additional paid-incapital. Conversion feature under reverse public merger transaction Under a reverse public merger transaction, the Notes convert at the sum of (a) the outstanding principal balance and unpaid accrued interest at the time of the transaction, plus (b) a Make-Whole Amount premium, defined in